Andrew X. Zhu, MD, PhD, of Massachusetts General Hospital, discusses study findings on pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (Abstract 209).
Mark Saunders, MD, PhD, of Christie Hospital, discusses study findings on tumor sidedness and the influence of chemotherapy duration on disease-free survival (Abstract 558).
Thierry André, MD, of Hôpital Saint-Antoine, and Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, discuss findings from their respective CheckMate-142 studies on nivolumab and ipilimumab in patients with DNA mismatch repair–deficient/microsatellite instability–high metastatic colorectal cancer (Abstracts 553, 554).
Basem Azab, MD, of the Sylvester Comprehensive Cancer Center, University of Miami, discusses the impact on overall survival when more than 2 months elapse between finishing neoadjuvant therapy and undergoing esophagectomy (Abstract 2).
David H. Ilson, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the merits of preoperative chemotherapy vs chemoradiotherapy, the role of targeted agents, recent results from genomic profiling, and whether PET scans can guide neoadjuvant treatment.
Kyaw L. Aung, MBBS, PhD, of Princess Margaret Cancer Centre, discusses early study findings on genomics-driven precision medicine for advanced pancreatic ductal carcinoma (Abstract 211).
